비뇨생식기 의약품 시장 : 적응증별, 제품별, 지역별(2025-2033년)

The global genitourinary drugs market size reached USD 33.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 39.8 Billion by 2033, exhibiting a growth rate (CAGR) of 1.8% during 2025-2033.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:

The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:

Breakup by Indication:

• Prostate Cancer
• Ovarian Cancer
• Bladder Cancer
• Cervical Cancer
• Renal Cancer
• Erectile Dysfunction
• Urinary Tract Infections
• Urinary Incontinence and Overactive Bladder
• Sexually Transmitted Diseases
• Interstitial Cystitis
• Hematuria
• Benign Prostatic Hyperplasia

Breakup by Product:

• Urological
• Hormonal Therapy
• Gynecological
• Anti-infectives
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

• 1.How big is the global genitourinary drugs market?
• 2.What is the expected growth rate of the global genitourinary drugs market during 2025-2033?
• 3.What are the key factors driving the global genitourinary drugs market?
• 4.What has been the impact of COVID-19 on the global genitourinary drugs market?
• 5.What is the breakup of the global genitourinary drugs market based on the indication?
• 6.What is the breakup of the global genitourinary drugs market based on the product?
• 7.What are the key regions in the global genitourinary drugs market?
• 8.Who are the key players/companies in the global genitourinary drugs market?
• Need more help?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Genitourinary Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Prostate Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Ovarian Cancer
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Bladder Cancer
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Cervical Cancer
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Renal Cancer
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Erectile Dysfunction
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Urinary Tract Infections
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast
• 6.8 Urinary Incontinence and Overactive Bladder
  • 6.8.1 Market Trends
  • 6.8.2 Market Forecast
• 6.9 Sexually Transmitted Diseases
  • 6.9.1 Market Trends
  • 6.9.2 Market Forecast
• 6.10 Interstitial Cystitis
  • 6.10.1 Market Trends
  • 6.10.2 Market Forecast
• 6.11 Hematuria
  • 6.11.1 Market Trends
  • 6.11.2 Market Forecast
• 6.12 Benign Prostatic Hyperplasia
  • 6.12.1 Market Trends
  • 6.12.2 Market Forecast

7 Market Breakup by Product

• 7.1 Urological
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hormonal Therapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Gynecological
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Anti-infectives
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Allergan plc (AbbVie Inc.)
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 SWOT Analysis
  • 13.3.2 Antares Pharma Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
  • 13.3.3 AstraZeneca plc
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
  • 13.3.4 Bayer AG
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 Bristol-Myers Squibb Company
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Genentech Inc. (Roche Holding AG)
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 SWOT Analysis
  • 13.3.7 GlaxoSmithKline plc
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Merck & Co. Inc.
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Novartis AG
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Pfizer Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Teva Pharmaceutical Industries Ltd.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials